Table 2.
Ref. | Country | Type of study | No. of patients1 | Area of origin and percentage (%) | HBsAg positive (%) |
Roussos et al[18] | Greece | Prospective | 130 | Eastern Europe: 86 | 15.33 |
Asia: 8.5 | 27.3 | ||||
Africa: 6.2 | 0 | ||||
Caruana et al[30] | Australia | Prospective | 329 | South east Asia | Laos 9.5 |
(Laos and Cambodia) | Cambodia 8 | ||||
Toro et al[16] | Spain | Prospective | 1303 | Latin America: 46 | 0 |
Sub-Saharan Africa: 23.7 | 15 | ||||
Eastern Europe: 9.4 | 0 | ||||
Northern Africa: 9.2 | 3.2 | ||||
Asia: 4.9 | Unknown | ||||
Hislop et al[29] | Canada | Prospective | 504 | China: 100 | 6 |
Majori et al[13] | Italy | Prospective | 182 | Sub-Saharan Africa: 100 | 9.3 |
Museru et al[24] | United States | Retrospective | 9570 | Asia: 24 | 10.72 |
Africa: 71 | |||||
Eastern Europe: 4 | |||||
Tafuri et al[12] | Italy | Prospective | 529 | Africa: 96.4 | 8.3 |
Asia: 3.6 | 0 | ||||
Milionis et al[19] | Greece | Prospective | 504 | Albania: 100 | 11.7 |
Lee et al[27] | United States | Prospective | 567 | Asia: 100 | 6 |
Levy et al[26] | United States | Prospective | 684 | South America: 96.4 | 0.3 |
1502 | Asia: 7.7 | 3.8 | |||
Mitchell et al[25] | United States | Retrospective | 27900000 | Latin America: 46.6 | 1.6 |
Africa: 3.36 | 11.1 | ||||
Mediterranean countries: 6 | 5 | ||||
Europe: 14.3 | 2.9 | ||||
South East Asia: 6.6 | 4 | ||||
Pacific Countries: 23.7 | 11 | ||||
Kallman et al[28] | United States | Prospective | 322 | Vietnam: 100 | 9.3 |
Veldhuijzen et al[22] | Holland | Prospective | 1090 | China: 100 | 8.5 |
Rivas et al[15] | Spain | Retrospective | 1493 | Sub-Saharan Africa: 100 | 8.4 |
McCarthy et al[10] | Canada, Europe, United States, Australia, New Zeland | Retrospective | 15421 | Africa: 41 | 12.5 |
Asia: 35.8 | 11.7 | ||||
South America: 16.1 | 2 | ||||
Eastern Europe: 4 | 0 | ||||
Vedio et al[21] | United Kingdom | Prospective | 229 | China: 100 | 8.7 |
Zuure et al[38] | The Netherlands | Prospective | 465 | Egypt: 100 | 1.1 |
Richter et al[39] | The Netherlands | Prospective | 959 | Eastern Asia: 100 | 2.2 |
Burgazli et al[20] | Germany | Prospective | 1287 | Turkey: 100 | 5 |
Mixson-Hayden et al[23] | United States | Prospective | 4890 | Somalia: 14.5 | 5.54 |
Asia: 86.5 | 6.84 | ||||
El-Hamad et al[17] | Italy | Prospective | 3728 | North Africa: 12.4 | 2.8 |
Eastern Europe: 44 | 6.9 | ||||
Sub-Saharan Africa: 21.4 | 3.7 | ||||
Asia: 16.8 (37 China) | 3.4 | ||||
Central-South America: 5.4 | 3.3 | ||||
Coppola et al[14] | Italy | Prospective | 882 | Northern Africa: 9 | 2.5 |
Sub-Saharan Africa: 50.3 | 13.9 | ||||
Eastern Europe: 22 | 6.2 | ||||
India-Pakistan Area: 14.3 | 3.2 |
Estimated cases;
It is not possible to differentiate for geographical area of origin;
Albania 22.4%;
HBV-DNA-positive. HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus.